Cortesi et al. BMC Cancer 2010, 10:90 http://www.biomedcentral.com/1471-2407/10/90 Table 1 Clinicopathological characteristics of patients according to familial risk group No family history (n = 4912) Family Risk Group Intermediate-Slightly increased risk (n = 691) High Risk (n = 320) Characterics Histotype Ductal Lobular Tubular Colloid Medullary Other Stage I II III IV X ER Positive Negative Unknown PgR Positive Negative Unknown Ki67 Low (0-19) High (20-100) 1109 Unknown Chemotherapy Yes No Hormone therapy Yes No N° 3936 606 93 64 26 187 2322 1546 802 216 23 3286 757 869 2796 1109 1007 2523 1007 1851 3061 2804 2108 % 80.1 12.3 1.9 1.3 0.5 3.9 47.3 31.5 16.4 4.4 0.5 66.8 15.4 17.8 56.9 22.5 20.6 51.4 22.5 20.6 37.7 62.3 57.1 42.9 N° 565 83 13 10 6 14 312 255 112 11 1 448 139 103 408 173 110 383 167 141 350 341 380 311 % 81.8 12.0 1.9 1.4 0.9 2.0 45.1 36.9 16.2 1.8 0.1 64.8 20.2 15.0 59.1 25.0 15.9 55.4 24.2 20.4 50.7 49.3 55.0 45.0 N° 251 44 2 0 13 10 141 127 48 1 3 147 149 24 135 162 23 185 103 32 106 214 106 214 % 78.4 13.7 0.6 0 4.1 3.2 44.1 39.7 15.0 0.3 0.9 45.9 46.6 7.5 42.2 50.6 7.2 57.8 32.2 10.0 33.1 66.9 33.1 66.9 Page 3 of 9 p NS NS NS NS < .0001 NS NS < .0001 NS <.0001 NS < .0001 < .0001 < .0001 < .0001 < .0001 < .0001 NS NS NS < .0001 < .0001 < .0001 < .0001 Abbreviations: ER, estrogen receptor; PgR, progesterone receptor between the groups (p = .17). The proportion of patients who received adjuvant chemotherapy was greater in the IS increased risk group than in the other two groups (p < .0001). The most frequent chemotherapy strategy was anthracycline-based followed by taxanes and the CMF regimen. The most frequently used first line che- motherapy regimen was platinum based, followed by a CMF scheme. The proportion of patients who received adjuvant hormone therapy was lower in the H risk group than in the other two groups, according to the negative hormonal receptor status (p < .0001). Mutational Analysis The BRCA1 mutational analysis was only performed in patients belonging to the H and IS risk groups, with a 22.8% (73/320) and 1.0% (7/691) mutation rate, respec- tively. In total, 80 patients were BRCA1 carriers. Survival analysis Overall, 5923 patients were followed until December 2006, resulting in a median follow-up time of 72 months. In all, 1302 deaths (1074 sporadic, 174 IS increased risk, and 54 H risk) and 1137 relapses (884 sporadic, 186 IS increased risk, and 67 H risk) were reported. The estimated 10-year overall survival rate was 82% for the H risk patients, 75% for the IS increased risk group, and 73% for patients with sporadic breast cancer (log-rank p < .0001; Fig. 1A). The estimated 10- year DFS was 72% in the H risk group, 70% in the IS increased risk group, and 75% in patients with sporadic